Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Phase II Study of Cabozantinib in Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer
2022-002419-48Phase 2Active
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in well-differentiated thyroid cancer (WDTC) and follicular carcinoma (FTC), sponsored by Spanish Group of Neuroendocrine Tumors. Started Jan 2023; status: active.
02
Drugs
cabozantinib
03
Conditions
well-differentiated thyroid cancer (WDTC)follicular carcinoma (FTC)
Beyond the preview
Go deeper on 2022-002419-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002419-48.